AbbVie Announces 223 Million Investment For New Biologics Manufacturing Facility In Singapore pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.
Spanning approximately 5,000 square feet, the facility, which has a key focus on ASEAN, builds upon Reckitt’s network of regional hubs across China, India, the US, and the UK.